Brief: Bioarctic Says Global License Agreement With Bristol Myers Squibb For Pyroglutamate-Amyloid-Beta Antibody Program Effective After Antitrust Clearance And Closing

BioArctic AB

20/02/2025 05:34

Feb 20 (Reuters) - BioArctic AB  BIOAb.ST :
    * BIOARCTIC'S GLOBAL LICENSE AGREEMENT WITH BRISTOL MYERS
SQUIBB
FOR PYROGLUTAMATE-AMYLOID-BETA ANTIBODY PROGRAM EFFECTIVE AFTER
ANTITRUST CLEARANCE AND CLOSING
    * BIOARCTIC AB - TO RECEIVE $100 MILLION UPFRONT PAYMENT
    * BIOARCTIC AB - AGREEMENT INCLUDES UP TO $1.25 BILLION IN
MILESTONES
    * BIOARCTIC AB - RETAINS OPTION TO CO-COMMERCIALIZE IN
NORDIC
REGION

Source text:  ID:nWkr95jbXk 
Further company coverage:  BIOAb.ST 

 ((Reuters.Briefs@thomsonreuters.com;))